ARS Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of neffy (EURneffy in the EU/UK), the first FDA and European Commission-approved needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. neffy uses a proprietary absorption enhancer called Intravail to deliver epinephrine intranasally at low doses. The company is also advancing a Phase 2b clinical trial for treatment-refractory chronic urticaria. neffy is approved in the U.S., EU, UK, Japan, Australia, and China, with regulatory review pending in Canada.
expected 2027-02-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001193125-26-097478 | EDGAR | 112K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042320 | EDGAR | 111K words |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034689 | EDGAR | 101K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009491 | EDGAR | 103K words |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005202 | EDGAR | 83K words |
| 2021-03-29 | 2020-12-31 | 0001193125-21-098283 | EDGAR | 96K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-05 | 2026-09-30 | 0001193125-26-449778 | EDGAR | 81K words |
| 2026-08-13 | 2026-06-30 | 0001193125-26-349140 | EDGAR | 79K words |
| 2025-11-10 | 2025-09-30 | 0001193125-25-273111 | EDGAR | 81K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107618 | EDGAR | 77K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-070900 | EDGAR | 73K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125924 | EDGAR | 67K words |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091776 | EDGAR | 68K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056967 | EDGAR | 65K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061996 | EDGAR | 70K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041310 | EDGAR | 69K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021997 | EDGAR | 67K words |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021234 | EDGAR | 38K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-05 | 0001193125-26-449748 | EDGAR | 3K words |
| 2026-08-13 | 0001193125-26-349127 | EDGAR | 4K words |
| 2026-07-17 | 0001193125-26-307773 | EDGAR | 1K words |
| 2026-03-09 | 0001193125-26-097467 | EDGAR | 4K words |
| 2025-11-10 | 0001193125-25-273107 | EDGAR | 4K words |
| 2025-09-29 | 0001193125-25-223228 | EDGAR | 73K words |
| 2025-08-28 | 0001193125-25-190202 | EDGAR | 1K words |
| 2025-08-13 | 0000950170-25-107617 | EDGAR | 4K words |
| 2025-06-26 | 0001193125-25-148922 | EDGAR | 1K words |
| 2025-05-14 | 0000950170-25-070899 | EDGAR | 4K words |
98 total filings indexed. 70 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001671858 |
| Ticker | SPRY |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ars-pharma.com |
| Listed | 2022-11-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SPRY (~200 tokens, structured JSON with cryptographic provenance)